Share this page: More
 

Ethel D. Weld

Richard Ambinder 

Department Affiliation: Primary: Medicine, Division of Clinical Pharmacology; Secondary: Pharmacology and Molecular Sciences, Division of Infectious Diseases
Degrees: M.D., University of Chicago Pritzker School of Medicine; Ph.D., Johns Hopkins University Bloomberg School of Public Health
Rank: Assistant Professor
Telephone Number: 410-502-8129
Fax Number: 410-955-9708
E-mail address:  eweld@jhmi.edu
School of Medicine Address: Osler 508, 600 N. Wolfe Street, Baltimore, MD 21287
Website:  Weld Hopkinsmedicine Webpage

 

Alternative delivery strategies for HIV prevention and treatment, and expanding treatment options for special populations with TB and HIV.

Ethel Weld’s active research areas include: 1) hands-on patient-oriented pharmacokinetic drug development studies related to topical microbicides for HIV pre-exposure prophylaxis (PrEP), 2) multicompartmental pharmacokinetic analyses of novel long-acting parenteral antiretroviral cabotegravir, 3) investigation of feasibility, safety, and acceptability to youth of long-acting parenteral antiretroviral formulations, and 4) the development of safety and dose-finding studies of novel medications for MDR TB in children. She has three years post-fellowship experience serving as PI and site PI of clinical research studies. Her primary research focus is to improve options for the treatment and prevention of HIV and MDR-TB, particularly in children and youth, and involve and investigate the safety, PK, and efficacy of less frequent dosing strategies as a method of adherence support. Dr. Weld is the Protocol Chair of IMPAACT 2005 (a study of the PK, safety, and tolerability of the novel nitroimidazole delamanid for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected children with MDR-TB), IMPAACT 2022 (a study of the safety, acceptability, and effectiveness of long-acting cabotegravir and rilpivirine for treatment of HIV in youth with non-adherence), and the clinical pharmacology lead for IMPAACT Concepts 5021 and 5018 (investigating safety and PK of one month of daily isoniazid and rifapentine for treatment of Latent Tuberculosis Infection (LTBI) in pregnant/ postpartum women and children, respectively). She serves as Protocol Pharmacologist for HPTN 083a and 084a, looking at the acceptability, safety, and PK of long-acting CAB as HIV PrEP among adolescents.


Representative Publications:

Novel ARV-based HIV Prevention Methods and Delivery Systems:

  • Weld, E.D., Hiruy, H., Guthrie, K.M., Fava, J., Vargas, S., Buckheit, K., Buckheit, R., Breakey, J., Fuchs, E., Hendrix, C. A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability. AIDS Research and Human Retroviruses 2017; 33(5): 440-447.  Pub Med Reference
  • Weld, E.D., Shieh, E.C., Fuchs, E.J., Hiruy, H., Buckheit, K.W., Buckheit, Jr., R.W., Breakey, J., Hendrix, C.W. Lubricant Provides Poor Rectal Mucosal HIV Coverage. AIDS Research and Human Retroviruses 2017; 33(8): 784-787. Pub Med Reference
  • Weld. E.D. “DREAM-01 Study: Tenofovir Rectal Douche as HIV PrEP: Safety, PK, PD, & Acceptability.”  Oral abstract at HIV Research for Prevention (HIVR4P) Conference, Madrid, Spain. October 24, 2018.   
  • Weld, E.D., Fuchs, E.J., et al. “Colorectal Distribution of Lymphocytes and Cell-Free HIV Surrogate in Autologous Seminal Plasma Following Simulated Anal Intercourse”, Late Breaker Poster Session, 9th IAS Conference on HIV Science Paris, France. July 24, 2017.


Integrated Biomedical and Socio-Behavioral Prevention Strategies:

  • Weld, E.D., Rana, M.S., Dallas, R.H., Camacho-Gonzalez, A.F., Ryscavage, P., Gaur, A.H., Chakraborty, R., Swindells, S., Flexner, C., Agwu, A.L. Interest of Youth Living with HIV in Long-Acting Antiretrovirals. JAIDS. 2018; 80(2):190-197. Pub Med Reference


Development of and Model-based dose-finding Strategies for Novel MDR-TB Drugs in Children with MDR-TB:

  • Weld, E.D., Dooley, K.E. “State of the Art Review of HIV-TB Co-management in Special Populations” (Invited State of the Art Review). Clinical Pharmacology & Therapeutics 2018; 104(6):1098-1109. Pub Med Reference
     
  • Weld, E.D., Garcia-Prats, A.J., Furin, J.J., Bailey, T.C., Hesseling, A.C., Dooley, K.E. The time has come: sparing injectables in pediatric MDR-TB. Lancet RM. 2017; 5(4): 245-246. [Epub Ahead of Print]  Pub Med Reference
     
  • Weld, E.D., Pau, A.K., Maartens, G., Dooley, K.E. Co-Treatment of Tuberculosis and HIV: Pharmacologic Considerations”, in “TB and HIV: A Formidable Alliance”, Springer, NY. Manuscript submitted for publication.
     
  • Seddon, J., Weld, E.D., Schaaf, H., Garcia-Prats, A., Soyeon, K., Hesseling, A. Conducting clinical trials for children with multidrug-resistant tuberculosis: why should we. The International Journal of Tuberculosis and Lung Disease Supplement –Pediatric Landscapes. Int J Tuberc Lung Dis. 2018; 22(5) 24-33.  Pub Med Reference

 


Other graduate programs in which Dr. Weld participates:  None